Alnylam Reports Fourth Quarter and Full Year 2020 Financials

 − Achieved Fourth Quarter and Full Year 2020 Global Net Product Revenues of $113 Million and $362 Million, Respectively –

− Achieved Regulatory Approvals of OXLUMO™ in the EU and U.S. and Leqvio®, by Partner Novartis, in the EU –

– Launched “Alnylam P⁵x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over the Next Five Years –

– Reported Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy –

– Provides 2021 Combined Net Product Revenue Guidance of $610-660 Million, in addition to Collaboration & Royalty Revenue and Operating Expense Guidance –

https://www.biospace.com/article/releases/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-and-highlights-recent-period-activity/